Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Villard, E.
Right arrow Articles by Soubrier, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Villard, E.
Right arrow Articles by Soubrier, F.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 273, Issue 39, 25191-25197, September 25, 1998


Induction of Angiotensin I-converting Enzyme Transcription by a Protein Kinase C-dependent Mechanism in Human Endothelial Cells*

Eric VillardDagger , Amalia Alonso§, Monique Agrapart, Mireille Challah, and Florent Soubrier

From INSERM Unité 358, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, and  INSERM Unité 460, Faculté de Médecine Xavier Bichat, Paris, France

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Angiotensin I-converting enzyme (ACE) has been implicated in various cardiovascular diseases; however, little is known about the ACE gene regulation in endothelial cells. We have investigated the effect of the protein kinase C activator phorbol 12-myristate 13-acetate (PMA) on ACE activity and gene expression in human umbilical vein endothelial cells (HUVEC). Our results showed a 3- and 5-fold increase in ACE activity in the medium and in the cells, respectively, after 24-h stimulation by PMA. We also observed an increase in the cellular ACE mRNA content starting after 6 h and reaching a 10-fold increase at 24 h in response to 100 ng/ml PMA as measured by ribonuclease protection assay. This effect was mediated by an increased transcription of the ACE gene as demonstrated by nuclear run-on experiments and nearly abolished by the specific PKC inhibitor GF 109203X. Our results indicate that PMA-activated PKC strongly increases ACE mRNA level and ACE gene transcription in HUVEC, an effect associated with an increased ACE secretion. A role for early growth response factor-1 (Egr-1) as a factor regulating ACE gene expression is suggested by both the presence of an Egr-1-responsive element in the proximal portion of the ACE promoter and the kinetics of the Egr-1 mRNA increase in HUVEC treated with PMA.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Angiotensin I-converting enzyme (ACE)1 is a dipeptidyl carboxypeptidase that generates the vasoconstrictor peptide and growth factor angiotensin II from angiotensin I and inactivates the vasodilator peptide bradykinin (1). ACE also cleaves other peptides such as substance P, enkephalins, neurotensin, and gonadotropin-releasing hormone, but these activities are of unknown physiological relevance (1).

ACE is a membrane-bound enzyme located mainly at the luminal face of endothelial cells (EC) in blood vessels (2). In the plasma, ACE is present as a soluble form originating mainly from EC by a proteolytic cleavage (3).

The level of ACE is stable in human plasma, and limited data are available on its regulation at the cellular or tissue level (4). In bovine aortic endothelial cells, ACE was shown to be increased slightly by glucocorticoids, density growth arrest, and ACE inhibitors (5-8). Glucocorticoids also induce ACE expression and activity in macrophages and rat vascular smooth muscle cells (9, 10). In the latter cells, the induction is synergistic with basic fibroblast growth factor (11). ACE induction is also observed in several pathological processes. After balloon injury in rat arteries, ACE is induced in vascular neointimal cells, and ACE inhibition has a beneficial effect on neointimal proliferation in this experimental model, decreasing the neointima/media ratio (12). ACE was shown to be induced in the aortic wall in different models of rat hypertension such as renovascular hypertension (13) or hypertension induced by chronic administration of the nitric oxide synthesis inhibitor Nomega -nitro-L-arginine-methyl ester (14). ACE expression is also increased in interstitial cells of the heart during renovascular hypertension (15).

Whether ACE induction plays an etiological role in pathological processes or simply reflects an endothelium activation is still a matter of debate. In the rat, ACE cDNA transfer in the vessel wall leads to an increased media/lumen ratio without systemic effects (16). In the Nomega -nitro-L-arginine-methyl ester model of hypertension, non-antihypertensive doses of ACE inhibitors seem to inhibit coronary vessel and cardiac remodeling (14).

The importance of ACE in cardiovascular diseases also comes from the possible implication of a polymorphism of the human ACE gene, which is associated with increased plasma and cellular ACE levels (17-19). The deletion allele of the insertion/deletion marker of the ACE gene was shown to be associated with an increased risk for myocardial infarction, left ventricular hypertrophy, vascular wall thickness, or vascular complications of diabetes (20). Results of these studies are not all concordant as can be expected from the modest relative risk increase that was found to be associated with the ACE genotype.

In various conditions, such as diabetes, platelet-activating factor, or basic fibroblast growth factor stimulation, an increase in ACE activity has been reported in vivo or in vitro in vascular smooth muscle cells and EC (11, 21-24). In these same experimental conditions, activation of PKC has also been reported in these cells (25-27). To determine more precisely how the ACE gene is regulated in EC, we investigated the effect of PMA-activated PKC on ACE gene expression and on ACE secretion. Our results indicate that PMA strongly increases ACE mRNA levels and ACE gene transcription in EC, an effect associated with an increased ACE secretion. A possible mechanism of ACE transcription induction is suggested by the presence of an Egr-1 responsive element in the ACE gene promoter and by the kinetics of Egr-1 mRNA increase by PMA in HUVEC, which is compatible with such an effect.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Materials-- Collagenase H, sonicated salmon sperm DNA, DNase I, proteinase K, RNase A, and T1 were from Boehringer Mannheim (Meylan, France). Phorbol 12-myristate 13-acetate (PMA), MCDB-131 medium, hydrocortisone, and bisindolylmaleimide I hydrochloride (GF 109203X) were from Sigma (L'Isle D'Abeau Chesnes, France). Fetal calf serum, phosphate-buffered saline, L-glutamine, penicillin, and streptomycin were from Seromed (Berlin, Germany). Human recombinant epidermal growth factor was from Euromedex (Souffelweyersheim, France).

Cell Culture-- HUVEC were isolated as described in detail by Jaffé et al. (28). The vein of an umbilical cord was washed with 20 ml of washing buffer (140 mM NaCl, 0.15 mM KH2PO4, 4 mM KCl, 0.5 mM Na2HPO4, and 2% glucose (w/v)). EC were dissociated from the vessel wall with 2% (w/v) collagenase H in washing buffer for 10 min at 37 °C. Cells were grown to confluence in a culture medium containing MCDB 131 medium, 20% heat-inactivated fetal calf serum, 2 mM L-glutamine, 100 units/ml penicillin, 100 µg/ml streptomycin, 10 ng/ml human recombinant epidermal growth factor, and 1 µg/ml hydrocortisone. Cells were maintained at 37 °C, 5% CO2 in a humidified incubator. Cells were characterized by staining for factor VIII- (Immunotech, Marseille, France) and CD31- (DAKO, Carpinteria, CA) related antigens. Cells were used at the first passage only. For all experiments, 24-h confluent cells were depleted of serum (0.4%) and of hydrocortisone/human recombinant epidermal growth factor for 24 h before PMA treatment. PMA and the PKC inhibitor GF 109203X stock solutions were made in dimethyl sulfoxide. In each experiment, the vehicle concentration was kept constant regardless of differences in the concentration of the compounds tested. For PKC inhibition, GF 109203X was added 1 h before a 24-h PMA treatment. Messenger RNAs were then harvested for ribonuclease protection assay.

ACE Activity Assay-- Control or PMA-treated cells from individual 25-cm2 plates were scraped after two washes in ice-cold phosphate-buffered saline. Cells and culture medium were stored frozen until assayed for ACE activity.

Cellular ACE Activity-- Cells in phosphate-buffered saline were pelleted and resuspended in 500 µl of 50 mM Tris, pH 7.4, 1% NaCl, and 8 mM CHAPS; then they were sonicated and centrifuged. ACE activity was determined essentially as described previously (29). Briefly, 100 µl of supernatant was incubated for 30 min at 37 °C with 25 µmol of the ACE substrate Z-Phe-His-Leu, and the produced dipeptide His-Leu was measured on a spectrofluorometer (Hitachi F2000) after labeling to the fluorescent 1,2-phtalicdicarboxaldehyde.

Medium ACE Activity-- ACE activity in the medium was measured on the radiolabeled synthetic substrate [glycine-1-14C]hippuryl-histidine-leucine as described previously (30). Activities were standardized to the total cellular protein content determined by the Bradford method (31).

Ribonuclease Protection Assay (RPA)-- Riboprobes were labeled with [alpha -32P]UTP (800 Ci/mmol, Amersham Pharmacia Biotech) using a commercially available kit (Riboprobe system, Promega) and T3 RNA polymerase. The RPA probe for ACE was obtained by NotI digestion of a plasmid (pBS-KS, Stratagene) containing the complete human ACE cDNA into its EcoRI site. This linearized template generates a riboprobe of 345 nucleotides and an expected protected ACE fragment of 280 bp (nucleotides 3742-4022 of the cDNA). For the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probe, we cloned into pCRscript (Stratagene) a RT-PCR product from nucleotide 671 to 1110. This clone was digested with Bsa I leading to a full-length probe of 270 nucleotides and a protected fragment of 210 bp. Total cellular mRNAs were isolated from HUVEC using commercially available reagents (Trizol, Life Technologies) based on a published method (32). Determination of the RNA concentration was achieved by spectrophotometry measuring A260 nm. RNA purity was evaluated by the 260 nm/280 nm A ratio and their quality by agarose gel electrophoresis and ethidium bromide staining.

RPAs were performed as described Ref. 33. In brief, 10 µg of total mRNA was incubated with both human GAPDH and human ACE riboprobes for 16 h at 45 °C in 40 mM PIPES, pH 6.4, 400 mM NaCl, 1 mM EDTA, and 80% (v/v) formamide. Single strand, nonhybridized RNA was digested by RNase treatment (40 µg/ml RNase A and 40 units/ml RNase T1) for 30 min at 37 °C. RNases were inactivated (15 min 37 °C, SDS-proteinase K), and samples were phenol-chloroform extracted before ethanol precipitation with 10 µg of yeast tRNA as carrier. Samples resuspended in 80% (v/v) formamide were heat denatured (5 min, 85 °C) and electrophoresed in a 4.5% polyacrylamide and 7 M urea denaturing gel. Gels were dried and exposed with two intensifying screens at -80 °C. Quantification of radioactive signals was performed by densitometric analysis using the NIH image software after autoradiogram scanning (model IIsi AGFA), except for dose dependence and PKC inhibition analysis and for the time course of Egr-1 mRNA increase analysis, for which quantification was performed by laser scanning of a PhosphorImager screen (model GS-525 molecular imager system, Bio-Rad).

Nuclear Run-on Analysis-- For each experiment, the cells from four confluent 225-cm2 plates were used. Two plates were treated for 24 h with PMA, and two were used as control. The cells were washed twice with ice-cold phosphate-buffered saline, scraped, collected by centrifugation (200 × g for 5 min at 4 °C), and lysed in 10 mM Tris, pH 8.4, 1.5 mM MgCl2, and 140 mM NaCl by the addition of a 10% Nonidet P-40 solution to a final concentration of 1% (v/v). The nuclei (20 × 106) were pelleted and resuspended in 200 µl of buffer (5 mM MgCl2, 500 mM sorbitol, 2.5% Ficoll, 0.008% spermidine, 50% glycerol, 1 mM dithiothreitol, 10 mM Tris-HCl, pH 7.5) and frozen immediately in liquid nitrogen until the labeling reaction was performed.

For in vitro transcription, the nuclei were thawed on ice, and 200 µl of labeling buffer (2.5 mM ATP, 1.25 mM GTP and CTP, 10 mM Tris-HCl, pH 8.3, 35 mM NH4Cl, 2 mM MgCl2, 10 units of RNase inhibitor, and 250 µCi of [alpha -32P]UTP (3,000 Ci/mmol)) was added. The nascent transcripts were labeled for 20 min at 27 °C, incubated with DNase I (15 min at 27 °C, Boehringer Mannheim), and extracted from pelleted nuclei (Trizol). RNAs were resuspended in diethylpyrocarbonate-treated distilled water and reprecipitated with ammonium acetate and ethanol. Aliquots of each labeling reaction were counted, and an equal number of cpm was added for each hybridization. Labeled transcripts were incubated for 48 h at 52 °C in 50% formamide, 2.5 × Denhardt's, 0.1% SDS, 2.5 × SSC (1 × SSC = 150 mM NaCl and 15 mM sodium citrate), 1 mM EDTA, 10 mM Tris, pH 7.5, 200 µg/ml sonicated salmon sperm DNA, and 100 µg/ml poly(A) (Amersham Pharmacia Biotech), and poly(G), with nylon membranes (Hybond N, Amersham Pharmacia Biotech) on which different linearized denatured plasmids were spotted: the complete human ACE cDNA, the complete rat GAPDH cDNA, a 688-bp cDNA fragment of rat beta -actin (nucleotides 472-1160), and pBluescipt KS as control. Membranes were washed twice with 2 × SSC at 65 °C for 30 min, once at 37 °C with 1 µg/ml RNase A, and once for 30 min at 37 °C in 2 × SSC. Membranes were exposed for autoradiography for 1 week at -80 °C with an intensifying screen.

RT-PCR-- RT reactions were performed with 1 µg of RNA, 10 pmol of oligo(dT)12-18 (Amersham Pharmacia Biotech), 200 units of Moloney murine leukemia virus reverse transcriptase (Life technologies), 40 units of ribonuclease inhibitor (RNaseOUT, Life Technologies), and a 1 mM concentration of each dNTP in a total volume of 20 µl of standard RT buffer. Samples were incubated for 1 h at 37 °C, and the reaction was stopped by heating for 10 min at 80 °C.

GAPDH and Egr-1 cDNA amplifications were performed in the same PCR to allow a relative quantification of Egr-1 mRNA. Touchdown PCR was performed as follows. First, 1 µl of cDNA was amplified with 10 pmol of 5'- and 3'-Egr-1 primers, 1 unit of Taq polymerase (Life Technologies), a 0.1 mM concentration of each dNTP, and 1 µCi of [alpha -33P]dATP (2,500 Ci/mmol, Amersham Pharmacia Biotech) in a total volume of 25 µl of Taq polymerase buffer. PCR cycles were done in the following conditions, each step lasting 30 s: 3 cycles at 68, 72, and 95 °C; 12 cycles at 66, 72, and 95 °C with Egr-1 primers. After the addition of 10 pmol of 5'- and 3'-GAPDH primers, 20 cycles were performed at 65, 72, and 95 °C. 10 µl of each amplification mixture was electrophoresed on 1.5% agarose gels. Expected size products were 480 bp for GAPDH and 253 bp for Egr-1. Primer sequences were as follows: GAPDH, 5'-CATCATCCCTGCCTCTACTGG-3' (forward) and 5'-GCCTTCCTCTTGTGCTCTTGCTG3-' (reverse); Egr-1, 5-'CTTTCCTCACTCGCCCACCAT-3' (forward) and 5'-CAGCACCTTCTCGTTCAG-3' (reverse). Gels were dried before quantification of radioactive signals.

Statistics-- Student's t test was used for comparison of ACE activities and run-on results, and significance was accepted for p < 0.05. For dose response, PKC inhibition, kinetics, and Egr-1 mRNA induction analysis, a repeated measures one-way analysis of variance was used. The p value was calculated by the Fisher test, and significance accepted for p < 0.05.

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

ACE activity was measured in HUVEC extracts and culture medium after a 24-h PMA treatment. As shown in Fig. 1, cellular ACE activity was increased 5-fold (70 ± 20 versus to 13 ± 8 pmol of Z-Phe-His-Leu/µg/min) after PMA treatment. Similarly, there was a 3-fold increase in ACE activity detected in the culture medium (4.2 ± 1.8 versus 1.5 ± 0.7 pmol of His-His-Leu/µg/min).


View larger version (19K):
[in this window]
[in a new window]
  		Fig. 1.   ACE activity in medium and cells after 24-h PMA treatment of HUVEC. Cells were growth arrested by serum depletion (0.4%) for 24 h before the experiments. ACE activity was compared in cells and culture medium between untreated (gray bar) and PMA-treated (black bar, 100 ng/ml, 24 h) cells and medium. The results are means ± S.D. of triplicate determinations of five independent experiments (five different umbilical cords were used). * indicates that the mean activity was significantly different between PMA and control by Student's t test, *p < 0.05.

An RPA was used to investigate if the increase in ACE activity was associated with an increase in the mRNA level. ACE mRNA was measured together with the GAPDH mRNA as an internal control for the amount of RNA hybridized. We looked at the kinetics of ACE mRNA induction. Cells were incubated in the presence or the absence of PMA (100 ng/ml) for different periods (from 0 to 48 h), and mRNAs were collected and analyzed by RPA. As shown in Fig. 2, the ACE mRNA increases after 6 h and reaches a maximum after 48 h. This result was obtained on cells originating from different umbilical cords (n = 4). Moreover, the experiment was made in two ways, either after the addition of PMA at the zero time (e.g. 24 h after serum depletion) and collecting mRNAs after the indicated time of incubation or by collecting all mRNAs at the same end time (e.g. 48 h after depletion) and adding PMA at various times before collection. These two methods gave identical results, indicating that the cells remain in a homogeneous state during the whole experiment and were similarly responsive to PMA regardless of the serum depletion duration. Moreover, a control without PMA treatment was done for each time of incubation, and no variation in the ACE/GAPDH mRNA ratio was detected (data not shown).


View larger version (20K):
[in this window]
[in a new window]
  		Fig. 2.   Time course of ACE mRNA increase upon PMA (100 ng/ml) incubation of HUVEC. Cells were growth arrested by serum depletion (0.4%) for 24 h before the experiments. Panel A, representative autoradiogram of one RPA experiment. ACE- and GAPDH-protected mRNA fragments are indicated (arrows) for the various times of PMA incubation. Panel B, bar graph showing the mean ± S.D. of the densitometric signal ratio (ACE/GAPDH mRNA) obtained in duplicate from four independent experiments at the various times of PMA incubation shown. * indicates that the mean mRNA ratio was significantly different from time zero by repeated measured one-way analysis of variance and the Fisher test, *p < 0.05.

We investigated the dose-response increase of ACE mRNA in response to PMA. The cells were incubated 24 h with various concentrations of PMA, and mRNAs were extracted before RPA analysis. As shown in Fig. 3, there is a marked increase in ACE mRNA from zero to 100 ng/ml PMA and a significant decrease of the PMA effect with 500 ng/ml. The concentration response for ACE mRNA level induction by PMA showed an EC50 of approximately 20 ng/ml. To determine if there was an increase in the transcription rate of ACE mRNA upon PMA treatment, run-on experiments were performed on isolated HUVEC nuclei. The results (Fig. 4) show that ACE gene transcription is undetectable without PMA stimulation, but a 6-fold increase in ACE mRNA transcription compared with control genes (beta -actin or GAPDH) is observed after stimulation.


View larger version (25K):
[in this window]
[in a new window]
  		Fig. 3.   Dose-dependent increase in ACE mRNA level upon PMA (100 ng/ml) incubation of HUVEC. Cells were growth arrested by serum depletion (0.4%) for 24 h before experiments. Panel A, representative autoradiogram of one RPA experiment. ACE- and GAPDH-protected mRNA fragments are indicated (arrows) for the various doses of PMA incubation. Panel B, bar graph showing the mean ± S.D. of the densitometric signal ratio (ACE/GAPDH mRNA) obtained in duplicate from five independent experiments at the various times of PMA incubation shown. * and ** indicate that the mean mRNA ratio was significantly different from time zero by repeated measured one-way analysis of variance and the Fisher test, *p < 0.05 and **p < 0.01, respectively.


View larger version (36K):
[in this window]
[in a new window]
  		Fig. 4.   Nuclear run-on assay of ACE gene transcription on HUVEC nuclei from PMA-treated or control cells. Cells were growth arrested by serum depletion (0.4%) for 24 h before experiments. Panel A, bar graph showing the mean ± S.D. of ACE mRNA level standardized to GAPDH (gray bar) or beta -actin (black bar), in the absence (-) or the presence (+) of 100 ng/ml PMA for 24 h. Panel B, representative autoradiogram of one experiment. * indicates that the mean densitometric signal was significantly different between +PMA and -PMA by Student's t test, *p < 0.05.

To confirm that the PMA-dependent stimulation of ACE involved activation of the PKC pathway, a PKC inhibitor (GF 109203X) was added to cultured HUVEC, either untreated or before PMA treatment. In PKC inhibitor-treated cells, we observed a dose-dependent inhibition of ACE mRNA level increase in the presence of PMA after 24 h (Fig. 5). The ACE/GAPDH ratio was significantly higher without PKC inhibitor than with 1 µM (10.2 ± 1.5 versus 3.2 ± 0.8, p < 0.01). When 5 µM inhibitor was added, the effect of PMA was nearly abolished. There was no significant difference in the ACE/GAPDH ratio between the control cells and the cells in the presence of 5 µM inhibitor.


View larger version (30K):
[in this window]
[in a new window]
  		Fig. 5.   PMA-dependent ACE mRNA level increase in HUVEC is inhibited by the specific PKC inhibitor GF 109203X. Cells were growth arrested by serum depletion (0.4%) for 24 h before experiments. The indicated concentrations of inhibitor were added 1 h before the PMA stimulation (100 ng/ml) for 24 h, and total mRNA was harvested and measured by RPA. Panel A, representative autoradiograms showing the ACE and GAPDH signals in the presence (+) or absence (-) of PMA, with various concentrations of PKC inhibitor (GF 109203X). ACE autoradiograms were overexposed compared with GAPDH. Panel B, bar graph showing the mean ± S.D. of the radioactive signal ratio (ACE/GAPDH mRNA) from three independent experiments performed in triplicate on PMA-treated (black bar) or control cells (gray bar) with various concentrations of inhibitor. * and ** indicate that the mean radioactive ratio was significantly different by one-way analysis of variance and the Fisher test, *p < 0.05 and **p < 0.01, respectively.

Semiquantitative RT-PCR analyses of Egr-1 mRNA of PMA-treated cells (100 ng/ml) for different periods of time (30 min-20 h) were performed (Fig. 6). PMA induced Egr-1 transcript levels in HUVEC within 30 min of exposure, and Egr-1 mRNA levels remained elevated for 20 h with maximum levels (6-fold increase) reached between 1 and 2 h of PMA treatment. To test whether the PMA-dependent Egr-1 mRNA increase involved activation of PKC pathway, GF 109203X at a concentration able to inhibit ACE transcription by PMA (5 µM) was added to cultured HUVEC under PMA treatment (100 ng/ml) (Fig. 6). In PKC inhibitor-treated cells, the effect of PMA was nearly abolished during the first 30 min of exposure, but the inhibition was not complete after longer exposure.


View larger version (21K):
[in this window]
[in a new window]
  		Fig. 6.   Time course of Egr-1 mRNA increase upon PMA (100 ng/ml) treatment of HUVEC and effect of the specific PKC inhibitor GF 109203X (5 µM). Cells were growth arrested by serum depletion (0.4%) for 24 h before the experiments. The PKC inhibitor was added 1 h before PMA stimulation, and total mRNA was harvested at various times of incubation and measured by RT-PCR. Representative autoradiograms of one RT-PCR experiment showing the Egr-1 and GAPDH signal in the absence (panel A) and presence (panel B) of PMA and in the presence of PMA and PKC inhibitor GF 109203X (panel C) are shown. Panel D, bar graph showing the mean ± S.D. of densitometric signal ratio (Egr-1/GAPDH mRNA) obtained in duplicate from four independent experiments at the various times of PMA treatment indicated. No significant differences were found between GF 109203X-treated cells and control cells except at 1 h. The mean mRNA ratio of HUVEC incubated in the presence of PMA was compared with the mean values obtained in the absence of PMA and in the presence of PMA upon PKC inhibitor treatment. * and ** indicate that the mean mRNA ratio was significantly different from controls by repeated measured one-way analysis of variance and the Fisher test, *p < 0.05 and ** p < 0.01, respectively.

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Treatment of HUVEC with PMA was responsible for a large increase in ACE secreted in the culture medium, in cellular ACE mRNA content, and in ACE transcription. These effects were mediated by PKC activation as shown by PKC inhibition experiments.

The increase in ACE activity in the culture medium, observed after 24 h of PMA treatment, is in part the result of the proteolytic release of membrane-anchored ACE as shown previously after PMA stimulation of mouse epithelial cells or Chinese hamster ovary cells stably transfected with mouse or human testicular ACE cDNA, respectively (34, 35). This solubilization process, or membrane shedding, has been described for various growth factors, cytokines, or receptors such as pro-transforming growth factor-alpha , colony-stimulating factor-1, c-kit oncogene ligand, tumor necrosis factor-alpha receptors, L-selectin, or beta -amyloid protein (36-42). This increase in secretion has been shown to be linked to PKC-dependent activation of a specific proteolytic mechanism in many cases (37, 38, 43). In the case of PMA-induced ACE secretion, it is a very rapid process that does not seem to be dependent on ACE gene transcription because it occurs when ACE is expressed under the control of a heterologous promoter (34, 35).

The important new finding reported in this study consists of the PMA-induced increase in endothelial cell ACE gene expression, which is associated with an increase in secretion but represents an independent process. The observed mRNA increase is nearly not yet detectable after 6 h of PMA treatment. This delay in the mRNA increase suggests that intermediate steps for mRNA induction are required because a post-translational mechanism, such as phosphorylation of preexisting transcription factors, would be expected to induce faster mRNA increase. Thus, a de novo expression of transcription factors is likely involved in ACE gene mRNA increase. The PMA induction of ACE mRNA lasted for 50 h, after which the effect was difficult to interpret because several factors were probably involved, such as PKC desensitization or cell injury by prolonged serum deprivation, as suggested by the increasing number of cells detached from the culture dishes after prolonged treatment periods.

Run-on experiments, performed on isolated HUVEC nuclei, show clearly that PMA induction of ACE mRNA acts at the transcriptional level. A well characterized signaling pathway of PKC is the activation of the AP1 transcription factor family, which interacts with the 12-O-tetradecanoylphorbol-13-acetate (TPA)-responsive-element (44), for which a consensus sequence is present in the 5'-flanking region of the ACE gene. Nevertheless, this possibility seems unlikely given the distance between the TPA-responsive element site and the start site in human ACE gene promoter position -5266 from transcription start site (45). Another candidate transcription factor is Egr-1, for which transcription is induced by PMA and a consensus-responsive element is present on the proximal human ACE gene promoter at position -59 (46). This potential responsive element overlaps a Sp1 consensus recognition element, similar to what is observed for the functional Egr-1-responsive element present in the platelet-derived growth factor-B gene promoter (47). A rapid increase of the Egr-1 mRNA was observed by RT-PCR amplification of RNA from PMA-exposed HUVEC, an effect that was shown previously in bovine aortic endothelial cells (47). Interestingly, induced Egr-1 mRNA expression precedes the earliest appearance of ACE mRNA in HUVEC exposed to PMA and is therefore compatible with the time course of ACE mRNA transcription after PMA treatment. The delay in ACE transcription activation, if compared with Egr-1, could be caused by the necessary accumulation of Egr-1 mRNA and protein and by post-translational modifications such as phosphorylation by PKC. This last step, which is known to increase the affinity of Egr-1 to its target genes (48, 49), might also explain the complete inhibition of PMA-induced ACE transcription by GF 109203X. In addition, different responses to phorbol esters exerted via PKC-independent pathways have already been described (50, 51) and could explain the incomplete inhibition of Egr-1 induction by GF 109203X.

An additional effect on ACE mRNA stability cannot be eliminated as it has been described for other genes, such as lactate dehydrogenase, c-fos, intercellular adhesion molecule-1, or ribonucleotide reductase, for which an increase in their mRNA half-life was shown after PMA treatment (52-55). Inversely, a decrease in mRNA stability was attributed to PMA for other genes, such as platelet-derived growth factor-A and -B (56, 57). In this study, a clear answer concerning the effect of PMA on ACE mRNA stability using actinomycin D could not be obtained. This was because of the low level of ACE mRNA expression in HUVECs in unstimulated conditions which did not allow the ACE mRNA to be quantified accurately after few hours of actinomycin D treatment. In addition, an unexplained increase in ACE mRNA was observed consistently after the 1st h of actinomycin D treatment when cells were stimulated by PMA, hampering the measurement of initial cellular ACE mRNA content. Despite these technical problems, no important differences between the ACE mRNA half-life of PMA-treated or control cells were detected (data not shown).

PKC activation represents a common pathway for several factors that are able to activate EC. These factors include hormones and growth factors such as vascular endothelial growth factor, basic fibroblast growth factor, and platelet-activating factor but also stressing conditions such as hypoxia or shear stress (26, 27, 58, 59). In response to this activation, EC synthesize several factors, such as intercellular adhesion molecule-1 (60), vascular cell adhesion molecule-1 (61), prostaglandin I2 (62), platelet-activating factor (63), platelet-derived growth factor-A and -B (64, 65), tissue factor (66), endothelin-1 (59), and cytoskeleton changes occur together with permeability changes (67, 68). This endothelial response to PKC thus represents a major step in the process of vascular diseases and may explain the ACE induction in conditions such as hypertension and diabetes.

Indeed, in the two-kidney-1clip hypertensive rat model of hypertension, ACE was shown to be increased in the vessel wall (69). The mechanical strain on the vessels walls, which is increased during hypertension, both on EC and vascular smooth muscle cells, is known to activate PKC in these two types of cells (70, 71) and might explain the ACE increase.

High glucose concentration is another condition that was shown to activate PKC in EC (25, 72). An increase in tissue and plasma ACE was observed during diabetes but was not explained clearly (73-76). According to our results one can hypothesize that ACE transcription might be induced by high glucose through PKC activation in EC. This mechanism could provide a biochemical basis for the beneficial effect of ACE inhibitor in preventing vascular complications of diabetes (77). Thus, ACE gene induction of expression by PKC activation might represent an important mechanism linking various diseases to ACE and the renin angiotensin system activation in vessels.

In summary, our results demonstrate a new transcription induction pathway of the ACE gene and its potential pathological implications. Additional experiments will allow the identification of PKC isoforms and the transcription factors involved in the ACE expression activation.

    ACKNOWLEDGEMENTS

We thank the staff of the department of obstetrics of hospital Tenon for supplying the umbilical cords. We thank Nathalie Chatelain for help in statistical analysis.

    FOOTNOTES

* This work was supported in part by INSERM and by a grant from Bristol-Myers Squibb.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Supported by a grant from the Astra laboratory and the French Society of Hypertension.

§ Supported by a grant from the IPSEN Foundation and the Fondation pour la Recherche Medicale.

To whom correspondence should be addressed. Tel.: 33-1-01-5372-4015; Fax: 33-1-01-5372-4020; E-mail: soubrier{at}inserm.chu-stlouis.fr.

The abbreviations used are: ACE, angiotensin I-converting enzyme; EC, endothelial cells; PKC, protein kinase C; PMA, phorbol 12-myristate 13-acetate; Egr-1, early growth response factor-1; HUVEC, human umbilical endothelial cells; GF 109203X, bisindolylmaleimide I hydrochloride; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid; RPA, ribonuclease protection assay; bp, base pair(s); GAPDH, glyceraldehyde-3-phosphate dehydrogenase; RT, reverse transcription; PCR, polymerase chain reaction; PIPES, 1,4-piperazinediethanesulfonic acid.
    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Corvol, P., Williams, T. A., and Soubrier, F. (1995) Methods Enzymol. 248, 283-305[Medline] [Order article via Infotrieve]
  2. Ryan, U. S., Ryan, J. W., Whitaker, C., and Chiu, A. (1976) Tissue Cell 8, 125-145[CrossRef][Medline] [Order article via Infotrieve]
  3. Beldent, V., Michaud, A., Wei, L., Chauvet, M.-T., and Corvol, P. (1993) J. Biol. Chem. 268, 26428-26434[Abstract/Free Full Text]
  4. Alhenc-Gelas, F., Richard, J., Courbon, D., Warnet, J. M., and Corvol, P. (1991) J. Lab. Clin. Med. 117, 33-39[Medline] [Order article via Infotrieve]
  5. Krulewitz, A. H., Baur, W. E., and Fanburg, B. L. (1984) Am. J. Physiol. 247, C163-C168[Abstract/Free Full Text]
  6. Dasarathy, Y., Lanzillo, J. J., and Fanburg, B. L. (1992) Am. J. Physiol. 263, L645-L649[Abstract/Free Full Text]
  7. Shai, S.-Y., Fishel, R. S., Martin, B. M., Berk, B. C., and Bernstein, K. E. (1992) Circ. Res. 70, 1274-1281[Abstract/Free Full Text]
  8. King, S. J., and Oparil, S. (1992) Am. J. Physiol. 263, C743-C749[Abstract/Free Full Text]
  9. Vuk-Pavlovic, Z., Kreofsky, T. J., and Rohrbach, M. S. (1989) J. Leukocyte Biol. 45, 503-509[Abstract]
  10. Fishel, R. S., Eisenberg, S., Shai, S.-Y., Redden, R. A., Bernstein, K. E., and Berk, B. C. (1995) Hypertension 25, 343-349[Abstract/Free Full Text]
  11. Fishel, R. S., Thourani, V., Eisenberg, S. J., Shai, S. Y., Corson, M. A., Nabel, E. G., Bernstein, K. E., and Berk, B. C. (1995) J. Clin. Invest. 95, 377-387
  12. Powell, J. S., Clozel, J., Müller, R. K. M., Kuhn, H., Hefti, F., Hosang, M., and Baumgartner, H. R. (1989) Science 245, 186-188[Abstract/Free Full Text]
  13. Shiota, N., Miyazaki, M., and Okunishi, H. (1992) Hypertension 20, 168-174[Abstract/Free Full Text]
  14. Takemoto, M., Egashira, K., Usui, M., Numaguchi, K., Tomita, H., Tsutsui, H., Shimokawa, H., Sueishi, K., and Takeshita, A. (1997) J. Clin. Invest. 99, 278-287[Medline] [Order article via Infotrieve]
  15. Challah, M., Nicoletti, A., Arnal, J. F., Philippe, M., Laboulandine, I., Allegrini, J., Alhenc-Gelas, F., Danilov, S., and Michel, J. B. (1995) Cardiovasc. Res. 30, 231-239[CrossRef][Medline] [Order article via Infotrieve]
  16. Morishita, R., Gibbons, G. H., Ellison, K. E., Lee, W., Zhang, L., Yu, H., Kaneda, Y., Ogihara, T., and Dzau, V. J. (1994) J. Clin. Invest. 94, 978-984
  17. Rigat, B., Hubert, C., Alhenc-Gelas, F., Cambien, F., Corvol, P., and Soubrier, F. (1990) J. Clin. Invest. 86, 1343-1346
  18. Costerousse, O., Allegrini, J., Lopez, M., and Alhenc-Gelas, F. (1993) Biochem. J. 290, 33-40
  19. Danser, A. H., Schalekamp, M. A., Bax, W. A., van den Brink, A. M., Saxena, P. R., Riegger, G. A., and Schunkert, H. (1995) Circulation 92, 1387-1388[Abstract/Free Full Text]
  20. Villard, E., and Soubrier, F. (1996) Cardiovasc. Res. 32, 999-1007[Free Full Text]
  21. Jandeleit, K., Rumble, J., Jackson, B., and Cooper, M. E. (1992) Clin. Exp. Pharmacol. Physiol. 19, 343-347[Medline] [Order article via Infotrieve]
  22. Kawaguchi, H., Sawa, H., and Yasuda, H. (1990) Biochim. Biophys. Acta 1052, 503-508[Medline] [Order article via Infotrieve]
  23. Kawaguchi, H., Sawa, H., Iizuka, K., and Yasuda, H. (1990) J. Hypertens. 8, 173-177[CrossRef][Medline] [Order article via Infotrieve]
  24. Okabe, T., Yamagata, K., Fujisawa, M., Takaku, F., Hidaka, H., and Umezawa, Y. (1987) Biochem. Biophys. Res. Commun. 145, 1211-1216[CrossRef][Medline] [Order article via Infotrieve]
  25. Lee, T. S., Saltsman, K. A., Ohashi, H., and King, G. L. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 5141-5145[Abstract/Free Full Text]
  26. Bussolino, F., Silvagno, F., Garbarino, G., Costamagna, C., Sanavio, F., Arese, M., Soldi, R., Aglietta, M., Pescarmona, G., Camussi, G., and Bosia, A. (1994) J. Biol. Chem. 269, 2877-2886[Abstract/Free Full Text]
  27. Kent, K. C., Mii, S., Harrington, E. O., Chang, J. D., Malette, S., and Ware, J. A. (1995) Circ. Res. 77, 231-238[Abstract/Free Full Text]
  28. Jaffe, E. A., Nachman, R. L., Becker, C. G., and Minick, C. R. (1973) J. Clin. Invest. 52, 2745-2756
  29. Piquilloud, Y., Reinharz, A., and Roth, M. (1970) Biochim. Biophys. Acta 206, 136-142[Medline] [Order article via Infotrieve]
  30. Cushman, D. W., and Cheung, H. S. (1971) Biochem. Pharmacol. 20, 1637-1648
  31. Bradford, M. M. (1976) Anal. Biochem. 72, 248-254[CrossRef][Medline] [Order article via Infotrieve]
  32. Chomczynsky, P., and Sacchi, N. (1987) Anal. Biochem. 162, 156-159[Medline] [Order article via Infotrieve]
  33. Gilman, M. (1993) in Current Protocols in Molecular Biology (Ausubel, F., Brent, R., Kingston, R., Moore, D., Seidman, J., Smith, J., and Struhl, K., eds), pp. 4.7.1-4.7.8, John Wiley and Sons, New York
  34. Ramchandran, R., Sen, G. C., Misono, K., and Sen, I. (1994) J. Biol. Chem. 269, 2125-2130[Abstract/Free Full Text]
  35. Ehlers, M. R. W., Scholle, R. R., and Riordan, J. F. (1995) Biochem. Biophys. Res. Commun. 206, 541-547[CrossRef][Medline] [Order article via Infotrieve]
  36. Ehlers, M. R. W., and Riordan, J. F. (1991) Biochemistry 30, 10065-10074[CrossRef][Medline] [Order article via Infotrieve]
  37. Bosenberg, M. W., Pandiella, A., and Massagué, J. (1993) J. Cell Biol. 122, 95-101[Abstract/Free Full Text]
  38. Downing, J. R., Roussel, M. F., and Sheer, C. J. (1989) Mol. Cell. Biol. 9, 2890-2896[Abstract/Free Full Text]
  39. Huang, E. J., Nocka, K. H., Buck, J., and Besmer, P. (1992) Mol. Biol. Cell 3, 349-362[Abstract]
  40. Porteu, F., Brockhaus, M., Wallach, D., Engelmann, H., and Nathan, C. F. (1991) J. Biol. Chem. 266, 18846-18853[Abstract/Free Full Text]
  41. Khan, J., Ingrham, R. H., Shirley, F., Migaki, G. I., and Kishimoto, T. K. (1994) J. Cell Biol. 125, 461-470[Abstract/Free Full Text]
  42. Buxbaum, J. D., Gandy, S. E., Cicchetti, P., Ehrlich, M. E., Czernick, A. J., Fracasso, R. P., Ramabhadran, T. V., Unterbeck, A. J., and Greengard, P. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 6003-6006[Abstract/Free Full Text]
  43. Pandiella, A., and Massagué, J. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 1726-1730[Abstract/Free Full Text]
  44. Hug, H., and Sarre, T. F. (1993) Biochem. J. 291, 329-343
  45. Villard, E., Tiret, L., Visvikis, S., Rakotovao, R., Cambien, F., and Soubrier, F. (1996) Am. J. Hum. Genet. 58, 1268-1278[Medline] [Order article via Infotrieve]
  46. Hubert, C., Houot, A.-M., Corvol, P., and Soubrier, F. (1991) J. Biol. Chem. 266, 15377-15383[Abstract/Free Full Text]
  47. Khachigian, L. M., Lindner, V., Williams, A. J., and Collins, T. (1996) Science 271, 1427-1431[Abstract]
  48. Huang, R. P., Fan, Y., deBelle, I., Ni, Z., Matheny, W., and Adamson, E. D. (1998) Cell Death Differ. 5, 96-106[CrossRef][Medline] [Order article via Infotrieve]
  49. Huang, R. P., and Adamson, E. D. (1994) Biochem. Biophys. Res. Commun. 200, 1271-1276[CrossRef][Medline] [Order article via Infotrieve]
  50. Blumberg, P. M., Acs, G., Acs, P., Areces, L. B., Kazaniet, M. G., Lewin, N. E., and Szallasi, Z. (1995) Agents Actions Suppl. 47, 87-100[Medline] [Order article via Infotrieve]
  51. Rozengurt, E., Sinnett-Smith, J., and Zugaza, J. L. (1997) Biochem. Soc. Trans. 25, 565-571[Medline] [Order article via Infotrieve]
  52. Huang, D., Hubbard, C. J., and Jungmann, R. A. (1995) Mol. Endocrinol. 9, 994-1004[Abstract/Free Full Text]
  53. Gonzalez-Espinosa, C., and Garcia-Sainz, J. A. (1996) Biochim. Biophys. Acta 1310, 217-222[Medline] [Order article via Infotrieve]
  54. Chen, F. Y., Amara, F. M., and Wright, J. A. (1994) Biochem. J. 302, 125-132
  55. Ohh, M., and Takei, F. (1994) J. Biol. Chem. 269, 30117-30120[Abstract/Free Full Text]
  56. Bhandari, B., Woodruff, K., and Abboud, H. E. (1994) Mol. Cell. Biochem. 140, 31-36[CrossRef][Medline] [Order article via Infotrieve]
  57. Bhandari, B., and Abboud, H. E. (1994) Mol. Cell. Endocrinol. 91, 185-191
  58. Xia, P., Aiello, L. P., Ishii, H., Jiang, Z. Y., Park, D. J., Robinson, G. S., Takagi, H., Newsome, W. P., Jirousek, M. R., and King, G. L. (1996) J. Clin. Invest. 98, 2018-2026[Medline] [Order article via Infotrieve]
  59. Kuchan, M. J., and Frangos, J. A. (1993) Am. J. Physiol. 264, H150-H156[Abstract/Free Full Text]
  60. Lane, T. A., Lamkin, G. E., and Wancewicz, E. (1989) Biochem. Biophys. Res. Commun. 161, 945-952[CrossRef][Medline] [Order article via Infotrieve]
  61. Deisher, T. A., Haddix, T. L., Montgomery, K. F., Pohlman, T. H., Kaushansky, K., and Harlan, J. M. (1993) FEBS Lett. 331, 285-290[CrossRef][Medline] [Order article via Infotrieve]
  62. D'Humiers, S., Russo-Marie, F., and Vargaftig, B. B. (1986) Eur. J. Pharmacol 131, 13-19[CrossRef][Medline] [Order article via Infotrieve]
  63. Heller, Bussolino, F., Ghigo, D., Garbarino, G., Pescarmona, G., Till, U., and Bosia, A. (1992) J. Immunol. 149, 3682-3688[Abstract]
  64. Hsieh, H.-J., Li, N.-Q., and Frangos, J.-A. (1991) Am. J. Physiol. 260, H642-H646[Abstract/Free Full Text]
  65. Mitsumata, M., Fishel, R. S., Nerem, R. M., Alexander, R. W., and Berk, B. C. (1993) Am. J. Physiol. 265, H3-H8[Abstract/Free Full Text]
  66. Terry, C. M., and Callahan, K. S. (1996) J. Lab. Clin. Med. 127, 81-93[CrossRef][Medline] [Order article via Infotrieve]
  67. Bussolino, F., Camussi, G., Aglietta, M., Braquet, P., Bosia, A., Pescarmona, G., Sanavio, F., D'Urso, N., and Marchisio, P. C. (1987) J. Immunol. 139, 2439-2446[Abstract]
  68. Grigorian, G. Y., and Ryan, U. S. (1987) Circ. Res. 61, 389-395[Abstract/Free Full Text]
  69. Arnal, J.-F., Battle, T., Rasetti, C., Challah, M., Costerousse, O., Vicaut, E., Michel, J.-B., and Alhenc-Gelas, F. (1994) Am. J. Physiol. 267, H1777-H1784[Abstract/Free Full Text]
  70. Mills, I., Cohen, C. R., Kamal, K., Li, G., Shin, T., Du, W., and Sumpio, B. E. (1997) J. Cell. Physiol. 170, 228-234[CrossRef][Medline] [Order article via Infotrieve]
  71. Wang, D. L., Wung, B. S., Peng, Y. C., and Wang, J. J. (1995) J. Cell. Physiol. 163, 400-406[CrossRef][Medline] [Order article via Infotrieve]
  72. Hempel, A., Maasch, C., Heintze, U., Lindschau, C., Dietz, R., Luft, F. C., and Haller, H. (1997) Circ. Res. 81, 363-371[Abstract/Free Full Text]
  73. Craven, P. A., and DeRubertis, F. R. (1989) J. Clin. Invest. 83, 1667-1675
  74. Liberman, J., and Sastre, A. (1980) Ann. Intern. Med. 93, 825-826
  75. Shiba, T., Inoguchi, T., Sportsman, J. R., Heath, W. F., Bursell, S., and King, G. L. (1993) Am. J. Physiol. 265, E783-E793[Abstract/Free Full Text]
  76. Van Dyk, D. J., Erman, A., Erman, T., Chen-Gal, B., Sulkes, J., and Boner, G. (1994) Eur. J. Clin. Invest. 24, 463-467[Medline] [Order article via Infotrieve]
  77. Marre, M., Chatellier, G., Leblanc, H., Guyenne, T.-T., Ménard, J., and Passa, P. (1988) Br. Med. J. 297, 1092-1095 s

Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
C. Kojima, A. Kawakami, T. Takei, K. Nitta, and M. Yoshida
Angiotensin-Converting Enzyme Inhibitor Attenuates Monocyte Adhesion to Vascular Endothelium through Modulation of Intracellular Zinc
J. Pharmacol. Exp. Ther., December 1, 2007; 323(3): 855 - 860.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Shimoda, G. Hashimoto, S. Mochizuki, E. Ikeda, N. Nagai, S. Ishida, and Y. Okada
Binding of ADAM28 to P-selectin Glycoprotein Ligand-1 Enhances P-selectin-mediated Leukocyte Adhesion to Endothelial Cells
J. Biol. Chem., August 31, 2007; 282(35): 25864 - 25874.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
K. Hasegawa, S. Wakino, S. Tatematsu, K. Yoshioka, K. Homma, N. Sugano, M. Kimoto, K. Hayashi, and H. Itoh
Role of Asymmetric Dimethylarginine in Vascular Injury in Transgenic Mice Overexpressing Dimethylarginie Dimethylaminohydrolase 2
Circ. Res., July 20, 2007; 101(2): e2 - e10.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
O. Saijonmaa, T. Nyman, and F. Fyhrquist
Atorvastatin inhibits angiotensin-converting enzyme induction in differentiating human macrophages
Am J Physiol Heart Circ Physiol, April 1, 2007; 292(4): H1917 - H1921.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
O. Saijonmaa, T. Nyman, and F. Fyhrquist
Regulation of angiotensin-converting enzyme production by nicotine in human endothelial cells
Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H2000 - H2004.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
G. G. Neri Serneri, M. Boddi, P. A. Modesti, M. Coppo, I. Cecioni, T. Toscano, M. L. Papa, M. Bandinelli, G. F. Lisi, and M. Chiavarelli
Cardiac Angiotensin II Participates in Coronary Microvessel Inflammation of Unstable Angina and Strengthens the Immunomediated Component
Circ. Res., June 25, 2004; 94(12): 1630 - 1637.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
O. Saijonmaa, T. Nyman, P. Stewen, and F. Fyhrquist
Atorvastatin completely inhibits VEGF-induced ACE upregulation in human endothelial cells
Am J Physiol Heart Circ Physiol, June 1, 2004; 286(6): H2096 - H2102.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. M. Day, G. Thiel, J. Lum, R. D. Chevere, Y. Yang, J. Stevens, L. Sibert, and B. L. Fanburg
Hepatocyte Growth Factor Regulates Angiotensin Converting Enzyme Expression
J. Biol. Chem., March 5, 2004; 279(10): 8792 - 8801.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
Y. Zhang, L. J. Bloem, L. Yu, T. B. Estridge, P. W. Iversen, C. E. McDonald, J. P. Schrementi, X. Wang, C. J. Vlahos, and J. Wang
Protein kinase C {beta}II activation induces angiotensin converting enzyme expression in neonatal rat cardiomyocytes
Cardiovasc Res, January 1, 2003; 57(1): 139 - 146.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
M. Eyries, M. Agrapart, A. Alonso, and F. Soubrier
Phorbol Ester Induction of Angiotensin-Converting Enzyme Transcription Is Mediated by Egr-1 and AP-1 in Human Endothelial Cells via ERK1/2 Pathway
Circ. Res., November 15, 2002; 91(10): 899 - 906.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
H.-D. Orzechowski, A. Gunther, S. Menzel, A. Zimmermann, H. Funke-Kaiser, R. Real, T. Subkowski, F. S. Zollmann, and M. Paul
Transcriptional Mechanism of Protein Kinase C-Induced Isoform-Specific Expression of the Gene for Endothelin-Converting Enzyme-1in Human Endothelial Cells
Mol. Pharmacol., December 1, 2001; 60(6): 1332 - 1342.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
R. M. Day, Y. Yang, Y. J. Suzuki, J. Stevens, R. Pathi, A. Perlmutter, B. L. Fanburg, and J. J. Lanzillo
Bleomycin Upregulates Gene Expression of Angiotensin-Converting Enzyme via Mitogen-Activated Protein Kinase and Early Growth Response 1 Transcription Factor
Am. J. Respir. Cell Mol. Biol., November 1, 2001; 25(5): 613 - 619.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
O. Saijonmaa, T. Nyman, R. Kosonen, and F. Fyhrquist
Upregulation of angiotensin-converting enzyme by vascular endothelial growth factor
Am J Physiol Heart Circ Physiol, February 1, 2001; 280(2): H885 - H891.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
N. Saadane, L. Alpert, and L. E. Chalifour
Altered molecular response to adrenoreceptor-induced cardiac hypertrophy in Egr-1-deficient mice
Am J Physiol Heart Circ Physiol, March 1, 2000; 278(3): H796 - H805.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Villard, E.
Right arrow Articles by Soubrier, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Villard, E.
Right arrow Articles by Soubrier, F.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 1998 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement